Marinus Pharmaceuticals Completes Targeted Enrollment in Pivotal Phase 3 Study for CDKL5 Deficiency Disorder
February 25, 2020 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences
February 24, 2020 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 14, 2020 16:05 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative...
Marinus Pharmaceuticals to Present Ganaxolone EEG Clinical Data in Status Epilepticus at the American Clinical Neurophysiology Society 2020 Annual Meeting
February 03, 2020 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
Marinus Provides Business Outlook for 2020
January 13, 2020 07:30 ET
|
Marinus Pharmaceuticals, Inc.
Enrollment on-track for CDKL5 Deficiency Disorder Phase 3 readout Q3 2020 Two additional late-stage clinical trials planned to initiate in 2020 Company presentation and live webcast at 38th Annual...
Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare Conference
January 07, 2020 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of...
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 13, 2019 16:43 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative...
Marinus Pharmaceuticals Announces Closing of $70 Million Public Offering of Common Stock and Concurrent Private Placement Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 13, 2019 16:01 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced the closing of an underwritten public offering of 32,200,000...
Marinus Pharmaceuticals Appoints Elan Ezickson to Board of Directors
December 12, 2019 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics...
Corrected Press Release: Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement
December 11, 2019 10:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced the pricing of an underwritten public offering of 28,000,000...